Shear-force Prion Amplification for Neurodegenerative Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing neurodegenerative diseases associated with protein misfolding or aggregation, such as Alzheimer's and Parkinson's, are limited in their ability to detect specific analytes early or preclinically, and existing techniques lack precision in differential diagnosis before symptom onset.
Innovation Solution
An analytical process that utilizes shear-force control to amplify and detect aggregated conformation prion proteins from native conformation proteins in biopsied samples, employing specific shear-force intensities to differentiate between disease states, with data comparison to pre-determined reference samples for accurate diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used to detect aggregated prion proteins, then the detection process is simple, but the detection precision and early diagnostic capability are insufficient
Solution Approach 1:
The diagnostic process is segmented into distinct stages: incubation of sample with native prion protein, application of controlled shear-force to amplify aggregated conformations, and detection. This segmentation allows each stage to be optimized independently, with shear-force control providing precise amplification of disease-specific aggregates while maintaining manageable overall process complexity
Solution Approach 2:
The method performs preliminary amplification of aggregated prion proteins through controlled shear-force application before detection. By pre-concentrating and amplifying the target analyte in the incubation and shear-force steps, the subsequent detection achieves high precision even for early-stage or preclinical samples with low aggregate levels
2Adaptability or versatility
If existing diagnostic techniques are applied, then the diagnostic process is straightforward, but the ability to differentiate between disease subtypes is limited
Solution Approach 1:
The method applies local quality by using disease-specific native prion protein variants as incubation partners. Each neurodegenerative disease subtype has characteristic aggregate structures that selectively interact with corresponding native proteins under controlled shear-force, enabling subtype-specific amplification and detection without requiring complex multiplexed assays
Solution Approach 2:
The diagnostic approach leverages parameter changes by varying shear-force intensity and incubation conditions to optimize amplification of different aggregate types. By adjusting these physical parameters, the method can differentiate between disease subtypes based on their distinct biophysical properties and amplification responses
3Loss of time
If traditional detection methods are used, then the assay is easy to perform, but early or preclinical detection capability is lacking
Solution Approach 1:
The method performs preliminary amplification of aggregated prion proteins through controlled shear-force application before detection. By pre-concentrating and amplifying the target analyte in the incubation and shear-force steps, the subsequent detection achieves high precision even for early-stage or preclinical samples with low aggregate levels
Solution Approach 2:
Native conformation prion proteins serve as intermediaries that bind to and amplify disease-specific aggregated conformations during the incubation and shear-force treatment. This intermediary mechanism enables sensitive detection of trace aggregates in preclinical samples by converting them into detectable quantities through selective amplification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early and precise differential diagnosis of neurodegenerative diseases by accurately amplifying and detecting aggregated prion proteins, allowing for preclinical detection and differentiation between disease subtypes based on shear-force intensity patterns.
Implementation Method 1
subjecting the admixture to at least one shear-force intensity that is controlled to have a uniform intensity having an intensity range of maximally 20% of one shear-force value
Data Source
AI summary
The invention provides an analytical process for analysing the presence of at least one aggregated conformation prion protein in a sample of body fluid or a sample of tissue and uses the dependency of the amplification of the aggregated conformation on the shear-force intensity applied to the native conformation prion protein, which is also dependent on the specific seed present in the admixture with native conformation prion protein, for specifically analysing for the presence of an aggregated conformation prion protein in the sample. The process of the invention contains the step of determining the content of aggregated conformation prion protein generated in admixture with the sample to be analysed using one shear-force intensity, preferably using least at two different shear-force intensities and the step of comparing data on these contents of generated prion protein having an aggregated conformation with data on the content of aggregated prion protein that is pre-determined, each at the same shear-force intensity for a mixture of the same native conformation prion protein with a reference sample as a seed.